| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities | |||||||||
Net loss | |||||||||
- | - | - | -8,041 | -4,995 | -3,300 | -1,084 | - | - | - |
Net loss | |||||||||
-1,657 | -25,005 | -2,515 | - | - | - | - | -1,659 | -1,956 | -1,983 |
Adjustments to reconcile net income to net cash provided by operating activities | |||||||||
Depreciation | |||||||||
718 | 338 | 339 | 368 | 343 | 258 | 247 | 169 | 97 | 71 |
Amortization of intangible assets | |||||||||
1,079 | - | - | - | - | - | - | - | - | - |
Loss on disposal of property and equipment | |||||||||
- | - | - | -1 | 0 | 4 | 0 | -0 | 1 | -1 |
Stock-based compensation | |||||||||
3,043 | 1,519 | 1,270 | 776 | 511 | 229 | 248 | 216 | 235 | 164 |
Amortization of deferred rent related to lease incentives | |||||||||
- | - | 127 | - | - | - | - | - | - | - |
Non cash lease expense | |||||||||
-512 | - | - | - | - | - | - | - | - | - |
Stock issued for services | |||||||||
- | - | 107 | 135 | 0 | 210 | 0 | - | - | - |
Write off of deferred financing costs | |||||||||
- | - | 68 | - | - | - | - | - | - | - |
Write off of deferred financing costs | |||||||||
- | - | - | 86 | - | - | - | - | - | - |
Write off of deferred financing costs | |||||||||
- | - | - | - | 0 | 13 | 56 | 78 | 74 | 0 |
Amortization of debt discount | |||||||||
- | - | 156 | 218 | 0 | - | - | - | - | - |
Loss on deconsolidation of biologistex | |||||||||
- | - | - | -2,785 | 0 | - | - | - | - | - |
Loss from equity method investment in SAVSU | |||||||||
-739 | -672 | -1,005 | 0 | - | - | - | - | - | - |
Gain on acquisition of SAVSU | |||||||||
10,108 | - | - | - | - | - | - | - | - | - |
Change in fair value of contingent consideration | |||||||||
50 | - | - | - | - | - | - | - | - | - |
Deferred income tax benefit | |||||||||
-1,541 | - | - | - | - | - | - | - | - | - |
Change in fair value of warrant liability | |||||||||
12,835 | 28,271 | - | - | - | - | - | - | - | - |
Other | |||||||||
-15 | 127 | - | - | - | - | - | - | - | - |
Amortization of deferred rent related to lease incentives | |||||||||
- | - | - | 126 | -126 | - | - | - | - | - |
Lease incentives received from landlord, net of amortization of deferred rent related to lease incentives | |||||||||
- | - | - | - | - | -37 | 52 | 861 | - | - |
Accretion and amortization on available for sale investments | |||||||||
- | - | - | -1 | -90 | -98 | 0 | - | - | - |
Change in operating assets and liabilities | |||||||||
Lease incentive received from landlord, net of amortization | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Accounts receivable, trade, net | |||||||||
290 | 2,024 | -172 | 264 | 27 | -107 | 409 | -53 | -208 | -23 |
Inventories | |||||||||
3,777 | 1,662 | 89 | 290 | 869 | 544 | -235 | -150 | -95 | -52 |
Prepaid expenses and other current assets | |||||||||
704 | 104 | - | - | - | - | - | - | - | - |
Prepaid expenses and other current assets | |||||||||
- | - | 181 | -73 | -15 | 23 | 117 | -84 | -28 | 17 |
Accounts payable | |||||||||
768 | -11 | 21 | 233 | 194 | -392 | 4 | 459 | 286 | -75 |
Accrued expenses and other current liabilities | |||||||||
-246 | 497 | - | - | - | - | - | - | - | - |
Accrued compensation and other current liabilities | |||||||||
- | - | 292 | -410 | -145 | 7 | 278 | 227 | -59 | 59 |
Accrued interest | |||||||||
- | - | 152 | 97 | 0 | - | - | - | 670 | - |
Deferred rent | |||||||||
- | - | -65 | - | - | - | - | - | - | - |
Other liabilities | |||||||||
-81 | - | - | - | - | - | - | - | - | - |
Other | |||||||||
-142 | -16 | - | - | - | - | - | - | - | - |
Accrued interest, related parties | |||||||||
- | - | - | - | - | 177 | 742 | 733 | - | - |
Deferred rent | |||||||||
- | - | - | 27 | 36 | 39 | 0 | 76 | - | - |
Net cash used in operating activities | |||||||||
- | - | - | - | -4,973 | - | - | - | - | - |
Deferred rent | |||||||||
- | - | - | - | - | - | - | - | 12 | - |
Accrued interest, related parties | |||||||||
- | - | - | - | - | - | - | - | - | 588 |
Deferred revenue | |||||||||
- | - | - | - | - | - | -109 | -20 | -20 | -20 |
Net cash provided by operating activities | |||||||||
1,213 | 2,348 | 605 | -4,326 | - | -3,162 | 146 | 854 | -989 | -1,252 |
Cash flows from investing activities | |||||||||
Investment in Sexton | |||||||||
1,500 | - | - | - | - | - | - | - | - | - |
Investment in iVexSol convertible debt | |||||||||
1,000 | - | - | - | - | - | - | - | - | - |
Investment in equity investment SAVSU | |||||||||
- | - | - | - | 1,409 | 7,952 | 0 | - | - | - |
Sales/maturities of available-for-sale investments | |||||||||
- | - | - | 1,650 | 7,067 | 402 | 0 | - | - | - |
Cash received from sale of property and equipment | |||||||||
- | - | - | - | - | 4 | 0 | 1 | 2 | 0 |
Costs associated with internal use software development | |||||||||
- | - | - | 1,113 | 1,283 | 0 | - | - | - | - |
Purchase of property and equipment | |||||||||
675 | 500 | 144 | 143 | 134 | 589 | 236 | 1,151 | 93 | 28 |
Purchase of assets held for lease | |||||||||
1,655 | - | - | - | - | - | - | - | - | - |
Investment in SAVSU | |||||||||
- | 6,000 | - | - | - | - | - | - | - | - |
Net cash used in investing activities | |||||||||
-27,018 | -6,500 | -144 | 392 | - | -8,135 | -236 | -1,150 | -91 | -28 |
Cash flows from financing activities | |||||||||
Stock issue from private equity transaction | |||||||||
- | 20,000 | - | - | - | - | - | - | - | - |
Payment of costs related to Stock Issuances | |||||||||
- | - | 9 | 0 | - | - | - | - | - | - |
Proceeds from note payable | |||||||||
- | - | - | - | - | - | - | 475 | 1,095 | 1,145 |
Payments on equipment loan | |||||||||
- | - | 13 | 0 | - | - | - | - | - | - |
Payments on finance lease obligations | |||||||||
- | - | 11 | 0 | - | - | - | - | - | - |
Net cash provided by (used in) investing activities | |||||||||
- | - | - | - | 4,239 | - | - | - | - | - |
Proceeds from note payable to related party | |||||||||
- | - | 1,000 | 3,000 | - | - | - | - | - | - |
Proceeds from note payable to related party | |||||||||
- | - | - | - | 0 | - | - | - | - | - |
Proceeds from exercise of common stock options | |||||||||
1,181 | 508 | 3,978 | 278 | 368 | - | - | - | - | - |
Proceeds from exercise of warrants | |||||||||
574 | 12,392 | - | - | - | - | - | - | - | - |
Payments for redemption of preferred stock | |||||||||
- | 4,250 | - | - | - | - | - | - | - | - |
Payments of preferred stock dividends | |||||||||
- | 436 | 106 | 0 | - | - | - | - | - | - |
Other | |||||||||
-159 | -68 | - | - | - | - | - | - | - | - |
Proceeds from exercise of common stock options | |||||||||
- | - | - | - | - | 83 | 50 | 0 | - | - |
Deferred costs paid related to potential stock issuance | |||||||||
- | - | 43 | 111 | 0 | - | - | - | - | - |
Net cash provided by financing activities | |||||||||
- | - | - | - | 368 | - | - | - | - | - |
Proceeds from sale of common stock, net of expenses | |||||||||
- | - | - | - | - | 13,596 | 0 | - | - | - |
Net cash provided by financing activities | |||||||||
1,596 | 28,146 | 4,796 | 3,166 | - | 13,679 | 50 | 475 | 1,095 | 1,145 |
Net increase (decrease) in cash and cash equivalents | |||||||||
-24,209 | 23,994 | 5,257 | -767 | -365 | 2,382 | -40 | 179 | 13 | -135 |
Non-cash investing and financing activities | |||||||||
Purchase of property and equipment not yet paid | |||||||||
29 | 54 | 22 | 0 | - | - | - | - | - | - |
Deferred financing costs from issuance of warrants (See Note 7) | |||||||||
- | - | - | - | - | - | - | 137 | - | - |
Deferred financing costs from issuance of warrants (See Note 7) | |||||||||
- | - | - | - | - | - | - | - | 89 | - |
Preferred stock issued to convert related party note payable and accrued interest | |||||||||
- | - | 4,250 | - | - | - | - | - | - | 97 |
Purchase of equipment with debt | |||||||||
- | - | - | 0 | - | - | - | - | - | - |
Proceeds from issuance of common stock on exercise of common stock options not received as of year-end | |||||||||
- | - | - | - | 32 | 0 | - | - | - | - |
Financing costs not yet paid | |||||||||
- | - | - | 374 | 0 | - | - | - | - | - |
Acquisition of intangible asset from non-controlling interest (See Note 1) | |||||||||
- | - | - | - | - | 2,215 | 0 | - | - | - |
Conversion of notes payable and related party accrued interest to equity, net of unamortized deferred finance costs (See Note 1) | |||||||||
- | - | - | - | - | 14,180 | 0 | - | - | - |
Costs incurred for capitalized internal use software not paid as of quarter end (amounts are included in liabilities) | |||||||||
- | - | - | - | 415 | 0 | - | - | - | - |
Stock issued for services in prior period included in liabilities at prior year-end | |||||||||
- | 36 | 36 | 0 | - | - | - | - | - | - |
Reclassification of warrant liabilities to equity upon exercise | |||||||||
1,749 | 19,378 | - | - | - | - | - | - | - | - |
Receivables converted to equity investment in SAVSU | |||||||||
- | 150 | - | - | - | - | - | - | - | - |
Preferred stock issuance costs not yet paid | |||||||||
- | - | - | 26 | 0 | - | - | - | - | - |
Capital lease obligations incurred for purchase of equipment | |||||||||
- | - | 52 | 0 | - | - | - | - | - | - |
Purchase of equipment with debt | |||||||||
- | 18 | 39 | - | - | - | - | - | - | - |
Legal fees for private equity transaction not yet paid | |||||||||
- | 44 | - | - | - | - | - | - | - | - |
SAVSU [Member] | |||||||||
Net loss | |||||||||
- | 1,900 | - | - | - | - | - | - | - | - |
Cash acquired in acquisition of SAVSU | |||||||||
1,251 | - | - | - | - | - | - | - | - | - |
Stock consideration | |||||||||
19,932 | - | - | - | - | - | - | - | - | - |
Astero [Member] | |||||||||
Acquisition of Astero Bio, net of cash acquired | |||||||||
12,439 | - | - | - | - | - | - | - | - | - |
CBS Acquisition [Member] | |||||||||
Acquisition of Astero Bio, net of cash acquired | |||||||||
11,000 | - | - | - | - | - | - | - | - | - |
Stock consideration | |||||||||
4,000 | - | - | - | - | - | - | - | - | - |